Omaxe · NSE: OMAXE · BSE: 532880
Q4 FY24 results · Jan–Mar 2024
Omaxe reported revenue from operations of ₹535.58 crore (up 85.0% from Q4 FY23) and net loss of ₹143.59 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 535.58 | 289.47 | +85.0% | 599.21 | −10.6% |
| Other income | 6.74 | 8.70 | −22.5% | 2.69 | +150.6% |
| Total income | 542.32 | 298.17 | +81.9% | 601.90 | −9.9% |
| Profit before share of associates & JVs and tax | (191.37) | (142.72) | Loss widened | (81.76) | Loss widened |
| Share of profit/(loss) of associates & JVs | 0.14 | 0.00 | 0.05 | ||
| Net profit for the period | (143.59) | (104.39) | Loss widened | (71.77) | Loss widened |
| Attributable to shareholders of the company | (145.05) | (105.47) | Loss widened | — | — |
| EPS, basic (₹) | (7.93) | (5.77) | Loss widened | (3.66) | Loss widened |
| Net margin (%) | -26.8 | -36.1 | -12.0 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.55 | 166.11 | +1.5% | 220.64 | −23.6% |
| Other income | 5.38 | 4.80 | +12.1% | 2.41 | +123.2% |
| Total income | 173.93 | 170.91 | +1.8% | 223.05 | −22.0% |
| Profit before tax | (73.06) | (73.79) | Loss narrowed | (46.50) | Loss widened |
| Net profit for the period | (52.77) | (58.00) | Loss narrowed | (36.45) | Loss widened |
| EPS, basic (₹) | (2.89) | (3.17) | Loss narrowed | (1.99) | Loss widened |
| Net margin (%) | -31.3 | -34.9 | -16.5 |
Consolidated
- Filed with BSE
- 19 Jul 2024, 17:28 IST
- Board meeting
- 28 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 Jul 2024, 17:28 IST
- Board meeting
- 28 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE